top of page

Pre-Selection of patients who would respond to combination of chemotherapy and low dose immunotherapy using human histoculture platform

Farcast_SITC_2023 poster_LDN.jpg

The Farcast TruTumor platform provides the unique opportunity to identify patients who would truly benefit from treatment with chemotherapy (CT) + Low Dose Nivolumab (LDN) in combination. Furthermore, TruTumor response prediction showed 100% concordance with an observational trial where patients were treated with CT+LDN.

Enter your details to see the full poster now

bottom of page